NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.42B
This Quarter Return
+18.5%
1 Year Return
+12.08%
3 Year Return
+99.82%
5 Year Return
+98.46%
10 Year Return
+612.59%
AUM
$1.29B
AUM Growth
+$1.29B
(-15%)
Cap. Flow
-$294M
Cap. Flow
% of AUM
-22.75%
Top 10 Holdings %
Top 10 Hldgs %
58.27%
Holding
48
New
1
Increased
5
Reduced
14
Closed
7
Top Buys
| 1 |
CBAY
Cymabay Therapeutics
CBAY
|
$21.9M |
| 2 |
4D Molecular Therapeutics
FDMT
|
$5.42M |
| 3 |
Vaxcyte
PCVX
|
$4.99M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$4.81M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
$2.83M |
Top Sells
| 1 |
Brookfield
BN
|
$61.4M |
| 2 |
Disc Medicine
IRON
|
$55.5M |
| 3 |
CTLT
CATALENT, INC.
CTLT
|
$54.7M |
| 4 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
$30.7M |
| 5 |
ASML
ASML
|
$21M |
Sector Composition
| 1 | Healthcare | 53.31% |
| 2 | Technology | 28.76% |
| 3 | Industrials | 8.35% |
| 4 | Communication Services | 4.78% |
| 5 | Consumer Discretionary | 3.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
ASML
ASML
$292B
| $143M | 11.07% |
197,760
-29,010
| -13% | -$21M |
|
2
Salesforce
CRM
$245B
| $112M | 8.66% |
530,500
-48,000
| -8% | -$10.1M |
|
3
LanzaTech
LNZA
$49.1M
| $108M | 8.35% |
15,814,845
| – | – |
|
4
Corcept Therapeutics
CORT
$7.35B
| $75.2M | 5.81% |
3,377,768
| – | – |
|
5
TSMC
TSM
$1.2T
| $71.7M | 5.54% |
710,780
| – | – |
|
6
Cable One
CABO
$909M
| $61.8M | 4.78% |
94,103
| – | – |
|
|
7
Disc Medicine
IRON
$2.07B
| $48.4M | 3.74% |
1,090,772
-1,250,000
| -53% | -$55.5M |
|
8
Edgewise Therapeutics
EWTX
$1.51B
| $47.1M | 3.64% |
6,071,703
| – | – |
|
9
Mirum Pharmaceuticals
MIRM
$3.71B
| $43.6M | 3.37% |
1,684,193
| – | – |
|
10
Apple
AAPL
$3.45T
| $43M | 3.32% |
221,460
-73,820
| -25% | -$14.3M |
|
|
11
Vaxcyte
PCVX
$4B
| $42.2M | 3.26% |
845,000
+100,000
| +13% | +$4.99M |
|
12
Alibaba
BABA
$322B
| $41.7M | 3.23% |
500,827
| – | – |
|
|
13
BioMarin Pharmaceuticals
BMRN
$11.2B
| $34.7M | 2.68% |
400,000
+32,620
| +9% | +$2.83M |
|
14
Arcellx
ACLX
$3.85B
| $31.6M | 2.44% |
1,000,000
-225,000
| -18% | -$7.11M |
|
|
SGEN
15
DELISTED
Seagen Inc. Common Stock
SGEN
| $30.8M | 2.38% |
159,986
+25,000
| +19% | +$4.81M |
|
|
BPMC
16
DELISTED
Blueprint Medicines
BPMC
| $28.4M | 2.19% |
448,804
| – | – |
|
17
Insmed
INSM
$28.8B
| $28.3M | 2.18% |
1,339,304
| – | – |
|
18
Amicus Therapeutics
FOLD
$2.34B
| $26.3M | 2.03% |
2,095,900
| – | – |
|
19
Alnylam Pharmaceuticals
ALNY
$58.5B
| $22.5M | 1.74% |
118,383
| – | – |
|
|
CBAY
20
DELISTED
Cymabay Therapeutics
CBAY
| $21.9M | 1.69% |
+2,000,000
| New | +$21.9M |
|
|
OKUR
21
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
| $21.8M | 1.69% |
3,330,377
-100,000
| -3% | -$656K |
|
|
22
Brookfield
BN
$98.3B
| $20.5M | 1.58% |
627,207
-1,881,623
| -75% | -$61.4M |
|
23
Pharvaris
PHVS
$1.39B
| $20.1M | 1.56% |
1,329,325
| – | – |
|
24
Crinetics Pharmaceuticals
CRNX
$2.92B
| $19.8M | 1.53% |
1,100,000
| – | – |
|
25
Rocket Pharmaceuticals
RCKT
$354M
| $18.3M | 1.41% |
920,000
| – | – |
|